MAPT and Alzheimer disease: Rapamycin, a selective inhibitor of target-of-rapamycin complex 1 (TORC1) and thus modulator of the mTOR pathway activity, improved learning and memory and reduced Aβ and tau pathology in the brains of AD mouse model (Caccamo et al., 2010; Spilman et al., 2010).